CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Greg Smith

Chief Executive Officer, IP Group

Search every verified Greg Smith interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Greg Smith, chief executive officer of IP Group, discussed the company's first-half 2026 results in several interviews and presentations. He reported that net asset value (NAV) per share rose 3.2% to 114 pence, with cash realisations exceeding £85 million year-to-date, surpassing the total for 2025. Smith noted progress toward the company's £250 million realisations target by 2027, citing proceeds from sources including Hinge Health, Centessa, and Monolith. He also highlighted de-risking in the portfolio's exposure to Pfizer's anti-obesity programme, mentioning that the combination therapy advanced to phase 2b and that positive clinical data was released for the lead programme. Smith described broad-based progress across portfolio companies, including Oxford Nanopore, Enterprise Therapeutics, Hysata, and Oxa, the latter completing a $100 million funding round and entering a joint venture with the Dubai Future Foundation. He also discussed new investments in quantum computing and future compute, as well as expansion of the company's third-party capital platform. Smith stated that the company prioritises value over speed in realisations and remains confident in its ability to deliver against its targets.

Recent appearances

Verified interview transcripts

Notable quotes

“Yeah. So, this is a theme that I've been talking about for quite a long time. So, it's very encouraging to see two new mandates completing signing during the year. I said at the time of the full year when we announced the Abedine partnership and that I hoped we'd be able to deliver another one and actually the climate catalyst one signed and announced I think within a couple of weeks of the full year results actually”

“Yeah, I think that's the right conclusion to reach. As you say, we're making good progress against that 250 million. I remember the process of setting that what we consider to be quite a stretching objective back at the beginning of 2025 and at that point it was getting on for more than half of our market cap at the time. So we set ourselves an ambitious target to try and monetize some of that now value into cash and”

“The Pfizer programs remain one of the most significant value drivers within the portfolio. And so again, we're encouraged by the progress we've seen so far during 2026, I would say during the first half. It was the Berobenatide and amylin combination that advanced into phase 2b, and Pfizer also released some additional data that was positive from the lead program. That's in phase three. So both developments reduced r”

“We're definitely encouraged by the progress that we've made. You know, having generated more than 150 million of proceeds since the start of 2025, we're already more than 60% of that target with over a year remaining. I think, importantly, those proceeds have come from a range of different sources that includes Hinge Health, Centessa but also monolith, and that demonstrates the breadth of our portfolio and the abilit”

“The number one priority for the group this year was to return the business to NAV per share growth. And I was very pleased to say that we did exactly that.”

“We've got a lot of confidence in the business and that was partly brought about because you know, we achieved sort of three key objectives this year in 2025. You know, we increased our NAV per share. We were able to realize 68 million from the portfolio and that enabled us to use some cash to reinvest in the portfolio. But, I think also worth pointing out we actually retired about 10% of our shares in issue during th”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →